VintaBio, which debuted in 2023 as a CDMO focused on cranking out viral vectors for cell and gene therapy production, is having its manufacturing facility and intellectual property ...
AstraZeneca may not need a major acquisition to sustain growth beyond 2030—but the British pharma is reportedly not stopping ...
Alnylam Pharmaceuticals is seeking a new chief commercial officer as the biopharma announced that its six-year CCO veteran ...
Vanda Pharmaceuticals’ action-packed TV ad for motion-sickness drug Nereus has irked the FDA, which accused (PDF) the company ...
Merck & Co. is chasing the finish line with its eye on one prize: a world without cancer. | In “From Our Pipeline to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results